focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Ice, evening. A small correction to your post. Avacta will have written up the trial protocol and had it accepted by the FDA and equivalent regulatory agencies. The actual selection and treatment of patients will be done by Oncologists separated from Avacta. Avacta will be paying Sloan Kettering Memorial, and other cancer centres, but they won’t have direct ‘hands on’ the patients.
This makes the data more reliable and robust.
Evening all.
Fingers crossed we get more data on ‘therapeutically relevant’ tumour cell levels. At present what we’ve been told is close to useless. Plain dox has therapeutically relevant levels achieved within its licensed dose. But it’s only effective in approx 20% of patients at this dose regime. Multi Drug Resistance is such a huge problem for doxorubicin. We need to see TME / tumour cell levels of AVA6000 released doxorubicin that is beating plain doxorubicin hands down. Either through shorter intervals between doses, higher free doxorubicin delivery at dose, or both. It’s difficult to find the rate of AVA6000 separation in presence of FAP in tumours, but one slide does show a massive release of free doxorubicin if AVA6000 is incubated in a FAP environment for 18 hours.
AACR can’t come quickly enough.
GLA
This:
“Well, what do you notice about Avacta’s poster? Oh look AVA6000 isn’t a prodrug anymore it’s a PEPTIDE DRUG CONJUGATE (PDC).
Why? Because prodrug only speaks of a one-off but PDC speaks of a groundbreaking platform.”
🙏👏👏👏👏👌
“ With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit”
Fast growing diagnostics??? So why sell it…
Rory, please take this as discussion not argument. I read what you posted about early stage Pharma and their valuations. Difficult to read, but it made sense. Yet at the same time there are Broker’s Notes suggesting the sp should be higher than the £1.20 it was at, for example.
The ‘science’ shows great promise. We need a businessman / woman to take this forward. Businesspeople employ scientists, it shouldn’t be the other way around.
“ I still think (more than ever with hindsight), that the "unexpected surprise" of more dosing after Cohort 4 scuppered the cash runway. Why it was a surprise I don't know. Was it the results? I guess it has to be, what else could it be?”
We can safely say Big Al likes a bit of hype… yet still manages to get caught out when the drug performs exactly as it’s meant to. Why TF were they surprised? That’s the bit I don’t get. It does what they wanted it to. Why wasn’t the chance of them getting it right factored in?
If Avacta get to give a proper presentation to the main audience, we’re looking good. If all the data out of P1aA1 Q3W - all 7 cohorts - is only worth a little poster, then WTF have they been hiding from us? I know it’s a safety trial, but these really big doses should have biopsy data that confirms significant uptake into the TME / cancer cells.
They aren’t reinstating 1b. It’s not in the RNS or the Turner Pope note.
“ The Company would, dependent on the data obtained during the Phase 1a and Phase 2 trials, anticipate commencing a potential Phase 3 trial in Q1 2026 for AVA6000 (also subject to funding and regulatory approval).”
We’ll have to see if this P3 is for indications other than or including STS.
Good afternoon everyone.
Re trials stopped early. Not teaching people to suck eggs:
Having a trial stopped early because of proven efficacy is every Pharma’s dream. Stopped early because of harm or no benefit is their nightmare.
Every participant within a trial will be under higher level surveillance and investigation. ADR - Adverse Drug Reactions are constantly being actively looked for. Likewise evidence of efficacy will also be looked for. Unfortunately it’s more common for a trial to be stopped for ADRs. Avacta has a dedicated ADR option if you ring the company switchboard.
But we’re on a winner here. So much is already known about plain doxorubicin, and liposomal doxorubicin, the trial(s) have a huge established dataset to compare against.
GLA
It is stupid to sell at a loss, I accept that. And yes, a bit of a knee jerk. I’ve lost trust. I pathologically hate criminals and people who lie. This goes beyond sentiment, AS has deliberately deceived people. Or he’s simply incompetent. The science is sound, the platform works. Al isn’t and doesn’t. I know the company isn’t going bust, so the shares should recover. I just want everything to settle. I want to see what happens with REX.
I know the SP can change here very quickly, I might well regret my actions. But likewise, a less than spectacular AACR and larger share drop to Heights might push the SP down even further.
I’m going to stick to the science if I post here. Still invested, just not as much.
Above all else I wish everyone a good weekend and better luck going forward.
I was 50% down and have sold the majority at this loss. Worse in the ISA. Not going to be a bitter troll here. I just want a little stability. I know the SP might rocket up, but likewise a drop might occur.
Difficult to trust anything coming from the company at present. I hope and pray the AACR results are good. We’ll get some direction once we know if it’s a poster or proper presentation. Second time I’ve been badly burnt by believing the hype from a CEO. The BGC needs to go.